Clinical Trial Update: A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ASP0367 (MA-0211) in pediatric male participants with Duchenne Muscular Dystrophy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ASP0367 (MA-0211) (ASP0367)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Duchenne Muscular Dystrophy (DMD) | Phase 1 | Status: TERMINATED